Multidisciplinary Decision-Making—ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study)
Purpose of Review We aimed to reach an Italian multidisciplinary consensus on some crucial aspects of treatment decision making in CRSwNP, following 2 years of clinical experience in order to support specialists in the management of CRSwNP in clinical practice. We addressed issues relating to therapeutic decision-making and shared criteria for the treatment choice, as well as appropriate timing and criteria for evaluating treatment response, and highlighted the need for repeated multidisciplinary assessments. Recent Findings A national survey has been conducted recently to understand how rhinology practice has changed in Italy with the advent of biologics and how this affects patients with uncontrolled, severe CRSwNP. Despite the many published consensus documents, practical recommendations, and protocols on the use of biologics in CRSwNP, heterogenous behaviors in practice are still observed mainly conditioned by the novelty of the topic. Summary The consensus procedure followed a modified Delphi approach. The scientific board included 18 otorhinolaryngologists and 8 allergists, who selected the 4 main topics to be addressed and developed overall 20 statements. Consensus on these statements was sought by a larger group of 48 additional experts, through two rounds of voting, the first web-based, the second in presence with discussion and possible refinement of the statements. The statements reaching an average score ≥ 7 at the second voting round were approved. Five statements were proposed for each of the following topics: baseline evaluation of patients eligible for biologic therapy; choice between different therapeutic options; assessment of the response to biologic treatment; multidisciplinary management. At the first voting round, 19 out of the 20 statements reached a mean score ≥ 7. Following the discussion and a few consequent amendments, at the second round of voting all the 20 statements were approved..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current allergy and asthma reports - 24(2024), 3 vom: März, Seite 143-154 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Corso, Eugenio [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Biological therapy |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. corrected publication 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11882-024-01135-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055267696 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055267696 | ||
| 003 | DE-627 | ||
| 005 | 20240419064719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11882-024-01135-z |2 doi | |
| 035 | |a (DE-627)SPR055267696 | ||
| 035 | |a (SPR)s11882-024-01135-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.84 |2 bkl | ||
| 084 | |a 44.78 |2 bkl | ||
| 100 | 1 | |a De Corso, Eugenio |e verfasserin |0 (orcid)0000-0001-5761-7018 |4 aut | |
| 245 | 1 | 0 | |a Multidisciplinary Decision-Making—ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. corrected publication 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review We aimed to reach an Italian multidisciplinary consensus on some crucial aspects of treatment decision making in CRSwNP, following 2 years of clinical experience in order to support specialists in the management of CRSwNP in clinical practice. We addressed issues relating to therapeutic decision-making and shared criteria for the treatment choice, as well as appropriate timing and criteria for evaluating treatment response, and highlighted the need for repeated multidisciplinary assessments. Recent Findings A national survey has been conducted recently to understand how rhinology practice has changed in Italy with the advent of biologics and how this affects patients with uncontrolled, severe CRSwNP. Despite the many published consensus documents, practical recommendations, and protocols on the use of biologics in CRSwNP, heterogenous behaviors in practice are still observed mainly conditioned by the novelty of the topic. Summary The consensus procedure followed a modified Delphi approach. The scientific board included 18 otorhinolaryngologists and 8 allergists, who selected the 4 main topics to be addressed and developed overall 20 statements. Consensus on these statements was sought by a larger group of 48 additional experts, through two rounds of voting, the first web-based, the second in presence with discussion and possible refinement of the statements. The statements reaching an average score ≥ 7 at the second voting round were approved. Five statements were proposed for each of the following topics: baseline evaluation of patients eligible for biologic therapy; choice between different therapeutic options; assessment of the response to biologic treatment; multidisciplinary management. At the first voting round, 19 out of the 20 statements reached a mean score ≥ 7. Following the discussion and a few consequent amendments, at the second round of voting all the 20 statements were approved. | ||
| 650 | 4 | |a Chronic rhinosinusitis with nasal polyps |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biological therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Response assessment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Multidisciplinary management |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Type 2 inflammation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dupilumab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Omalizumab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mepolizumab |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Pipolo, Carlotta |e verfasserin |0 (orcid)0000-0001-6628-2117 |4 aut | |
| 700 | 1 | |a Caminati, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Cantone, Elena |e verfasserin |0 (orcid)0000-0002-7389-2033 |4 aut | |
| 700 | 1 | |a Seccia, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Cecchi, Lorenzo |e verfasserin |0 (orcid)0000-0002-0658-2449 |4 aut | |
| 700 | 1 | |a Nettis, Eustachio |e verfasserin |0 (orcid)0000-0003-1383-105X |4 aut | |
| 700 | 1 | |a Garzaro, Massimiliano |e verfasserin |0 (orcid)0000-0001-9949-1177 |4 aut | |
| 700 | 1 | |a Ottaviano, Giancarlo |e verfasserin |0 (orcid)0000-0003-2433-4761 |4 aut | |
| 700 | 1 | |a Gelardi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Cavaliere, Carlo |e verfasserin |0 (orcid)0000-0002-0378-8935 |4 aut | |
| 700 | 1 | |a Heffler, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Pagella, Fabio |e verfasserin |0 (orcid)0000-0002-2244-373X |4 aut | |
| 700 | 1 | |a Pasquini, Ernesto |e verfasserin |4 aut | |
| 700 | 1 | |a Trimarchi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Gallo, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a La Mantia, Ignazio |e verfasserin |4 aut | |
| 700 | 1 | |a Torretta, Sara |e verfasserin |0 (orcid)0000-0002-8461-6042 |4 aut | |
| 700 | 1 | |a Mattavelli, Davide |e verfasserin |0 (orcid)0000-0001-7023-6746 |4 aut | |
| 700 | 1 | |a Caruso, Cristiano |e verfasserin |4 aut | |
| 700 | 1 | |a Matucci, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Vultaggio, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bellocchi, Gianluca |e verfasserin |0 (orcid)0000-0001-5341-3309 |4 aut | |
| 700 | 1 | |a Alicandri Ciufelli, Matteo |e verfasserin |0 (orcid)0000-0002-3479-297X |4 aut | |
| 700 | 1 | |a FM, Passali |e verfasserin |4 aut | |
| 700 | 1 | |a Senna, Gianenrico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current allergy and asthma reports |d Springer US, 2001 |g 24(2024), 3 vom: März, Seite 143-154 |w (DE-627)SPR022844430 |w (DE-600)2094153-5 |x 1534-6315 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:3 |g month:03 |g pages:143-154 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11882-024-01135-z |m X:SPRINGER |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.84 |q VZ |
| 936 | b | k | |a 44.78 |q VZ |
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 3 |c 03 |h 143-154 | ||